Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia

Puntos clave

• The analysis aims to compare the clinical efficacy and cost-effectiveness of zanubrutinib and acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.
• Conducted a number needed to treat (NNT) analysis.
• Compared treatment outcomes and costs between zanubrutinib and acalabrutinib.
• Focused on relapsed/refractory chronic lymphocytic leukemia patients.
• Zanubrutinib demonstrated more favorable clinical outcomes compared to acalabrutinib.
• Zanubrutinib was associated with lower costs in the population studied.
• High-risk CLL patients benefitted significantly from zanubrutinib.